Key statistics
On Tuesday, Shattuck Labs Inc (STTK:NSQ) closed at 1.26, 17.76% above the 52 week low of 1.07 set on Oct 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.21 |
---|---|
High | 1.40 |
Low | 1.20 |
Bid | 1.25 |
Offer | 1.31 |
Previous close | 1.13 |
Average volume | 2.17m |
---|---|
Shares outstanding | 47.73m |
Free float | 41.36m |
P/E (TTM) | -- |
Market cap | 53.93m USD |
EPS (TTM) | -1.85 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
- Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
- Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
- Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
- Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
- Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
- Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
- Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
More ▼